EBR Systems has submitted its WiSE wireless cardiac pacing system for Australian regulatory approval, opening a potential second commercial market after the United States. The application has entered a priority review pathway, but neither approval nor an assessment timetable is guaranteed.
- TGA application submitted for WiSE inclusion on the ARTG
- April 2026 Priority Review Determination expected to shorten the target evaluation period
- Potential Australian market entry for patients who have not benefited from conventional CRT
- FDA approval supports the application, but TGA approval remains outstanding
EBR Systems, Inc. (ASX:EBR) has formally put its wireless heart failure pacing system in front of Australia’s regulator, taking a significant step towards expanding WiSE beyond its current US market. The company has applied to the Therapeutic Goods Administration for inclusion of WiSE on the Australian Register of Therapeutic Goods.
Priority review moves WiSE to the front of the queue
The application follows the TGA’s grant of a Priority Review Determination in April 2026. That pathway is designed for medical devices addressing life-threatening or seriously debilitating conditions where there is a high unmet clinical need, and is intended to reduce the target evaluation period through front-of-queue treatment.
That is an acceleration mechanism, not a regulatory green light. EBR said the timing and outcome remain subject to the TGA’s assessment and cannot be guaranteed. The filing provides no launch date, revenue forecast or indication of how quickly Australian commercialisation could follow an approval.
WiSE targets patients underserved by conventional CRT
If included on the ARTG, WiSE could give Australian clinicians a leadless left-ventricular pacing option for heart failure patients who have failed to benefit from conventional lead-based Cardiac Resynchronisation Therapy. EBR describes WiSE as the world’s only wireless system in clinical use for stimulating the heart’s left ventricle, using a small implanted device rather than a coronary sinus lead.
The application is supported by WiSE’s US Food and Drug Administration approval and would, if successful, extend the product beyond its US-only WiSE availability, which an earlier regulatory update said was then limited to the United States. That makes the Australian filing commercially relevant, although ARTG inclusion would still be only one step in establishing local access, adoption and reimbursement.
Regulatory decision is the next material catalyst
Chief executive John McCutcheon said the submission was an important step towards making WiSE available outside the US, adding that EBR looked forward to working with the TGA through the Priority Review process. The immediate test is narrower and more concrete: whether the regulator accepts the application and grants ARTG inclusion for a device whose Australian market opportunity remains prospective.
Bottom Line?
The TGA submission opens a potentially important second market for WiSE, but the investment story still turns on the regulator’s decision and what follows it.
Questions in the middle?
- Will the TGA seek additional information or maintain the expected priority assessment pathway?
- If approved, how quickly could EBR establish Australian clinical adoption and reimbursement?
- Can Australian expansion add momentum while EBR continues building its US commercial infrastructure?